ライフサイエンスコーパス: PPI

1 ed empirically with a proton pump inhibitor (PPI).

2 omotion and changes in pre-pulse inhibition (PPI).

3 lex network of protein-protein interactions (PPI).

4 g of amoxicillin, clarithromycin and PPI (AC/PPI).

5 ptoms despite use of proton pump inhibitors (PPIs).

6 ce of PPI cessation (discontinued or resumed PPIs).

7 st line of compounds that inhibit PEX14-PEX5 PPI.

8 ing, but not the sound-scaling, component of PPI.

9 500 mg) twice daily, with ongoing label-dose PPI.

10 f D2R clusters associated with a decrease of PPI.

11 thereby achieving sensitive detection of the PPi.

12 e cells and permeability increased in HVs on PPIs.

13 cs of host-host, virus-host, and virus-virus PPIs.

14 mune cells also decreased in FD-stoppers off PPIs.

15 lel experimentation for the investigation of PPIs.

16 ated computational methods to better predict PPIs.

17 toring to predict the ability to discontinue PPIs.

18 mized by ICU site to H2RBs actually received PPIs.

19 nalysis, revealed ~380 previously unreported PPIs.

20 e genes in the EoE transcriptome reversed by PPIs.

21 ry proteins, 1,011 known PPIs, and 765 novel PPIs.

22 Ninety percent (52/58) of patients were on PPIs.

23 to have continued symptoms, even when taking PPIs.

24 l graph of drug-protein, disease-protein and PPIs.

25 Thirty-four participants (34%) discontinued PPIs.

26 ternative strategy to antagonize a myriad of PPIs.

27 days in past week) among participants taking PPIs.

28 gible impact on the proximate composition of PPIs.

29 h was strongly correlated (median: 0.98; 95% PPI: 0.66 to 0.98) with increases in testing.

30 ,689 (95% posterior predictive interval [95% PPI]: 1,023 to 14,182,310) infections occurred in the Un

31 e sequence with use of H2RBs and then use of PPIs (13 436 patients randomized by site to PPIs and 13

32 symptoms were currently on therapy (55.2% on PPIs, 24.3% on histamine-2 receptor blockers, and 24.4%

33 Among 3229 participants taking daily PPIs, 54.1% had persistent GERD symptoms.

34 idly converted into inorganic pyrophosphate (PPi), a potent inhibitor of calcification.

35 -condition screen identified 13,764 pairwise PPIs, a threefold increase over PPIs identified in one c

36 inhibition of the acoustic startling reflex (PPI; a marker of psychotic-like behavior), memory, locom

37 networks change, we quantified the relative PPI abundance of 1.6 million protein pairs in the yeast

38 onsisting of amoxicillin, clarithromycin and PPI (AC/PPI).

39 d 4.1% of patients randomized by ICU site to PPIs actually received H2RBs and an estimated 20.1% of p

40 ing acute postprandial effects on PPG and/or PPI after exposure to LES, either alone, with a meal, or

41 Immutable PPIs aggregate into highly connected 'core' network modu

42 ng administration of bisphosphonates, stable PPi analogs with antimineralization activity.

43 PPI and AF showed better protein efficiency ratio and EA

44 Here, we deconstruct the phenomenon of PPI and confirm several limitations of the methodology t

45 rging, which may reduce the use of long-term PPI and fundoplication, but the long-term safety and eff

46 by site-directed cross-linking revealed that PpiD and the established SecY partner protein YidC use a

47 Both PpiD and YidC contacted the lateral gate, the plug domai

48 PPIs (13 436 patients randomized by site to PPIs and 13 392 randomized by site to H2RBs).

49 Use of PPIs and histamine 2-receptor antagonists (H2RA) during

50 were randomized to the sequence with use of PPIs and then use of H2RBs and 25 ICUs were randomized t

51 coacervation between a pea protein isolate (PPI) and each pectin was investigated as a function of p

52 unctional properties of the protein isolate (PPI) and protein fractions from pumpkin seed were evalua

53 lex coacervates between pea protein isolate (PPI) and sugar beet pectin (SBP) at concentrated solutio

54 l for defining protein-protein interactions (PPIs) and elucidating architectures of large protein ass

55 e stability of protein-protein interactions (PPIs) and impact their functions, which may cause variou

56 ate, 68% of cases and 52% of controls used a PPI, and 16% of cases and 11% of controls used an H2RA.

57 onsists of 165 ciliary proteins, 1,011 known PPIs, and 765 novel PPIs.

58 ainly focused on the stabilization of native PPIs, and non-native PPIs have received little considera

59 This possibility suggests that these PPIs, and perhaps not the individual chaperones themselv

60 rtle-scaling and sound-scaling components of PPI are a function of the baseline startle response.

61 Mutable PPIs are less likely to co-express, co-localize, and be

62 A few 'immutable' PPIs are present across all conditions, while most 'muta

63 across all conditions, while most 'mutable' PPIs are rarely observed.

64 hat the experimental methods for identifying PPIs are time-consuming and expensive, it is important t

65 Protein-protein interactions (PPIs) are an essential part of correct cellular function

66 Protein-protein interactions (PPIs) are central to many biological processes.

67 Proton pump inhibitors (PPIs) are frequently used after kidney transplantation a

68 Protein-protein interactions (PPIs) are fundamental in many biological processes and u

69 Protein-protein interactions (PPIs) are involved in many of life's essential biologica

70 Proton pump inhibitors (PPIs) are used for the long-term treatment of gastroesop

71 Proton-pump inhibitors, PPIs, are considered effective therapy for stomach acid

72 As demonstrated with p53-MDM2 PPI as a model application, the right-handed d-sulfono-g

73 enables us to validate previously described PPIs as well as to identify novel NS1 interactors.

74 The therapeutic effectiveness of PPIs associated with a lack of toxicity indicates that t

75 Targeting PPIs associated with Mcl-1 presents many challenges for

76 Disruption of protein-protein interactions (PPIs) between Na(v)1.6 and fibroblast growth factor 14 (

77 prediction of protein-protein interactions (PPIs) between the host and a microbial species, includin

78 7), contributed to the beany-related odor of PPIs but much less than that in raw flours.

79 sted several adverse effects after long-term PPI, but these findings need to be confirmed before infl

80 Use of PPIs, but not H2RAs, is associated with a higher risk of

81 to rapidly identify the domains involved in PPIs by advancing the use of yeast two-hybrid technology

82 We hypothesized that PPIs can counteract IL-13-mediated esophageal epithelial

83 Primary outcome was tolerance of PPI cessation (discontinued or resumed PPIs).

84 itoring (off PPIs for >=7 days) and a 3-week PPI cessation intervention.

85 roach to identify candidates appropriate for PPI cessation is not available.

86 Next, we showed that Ppid colocalized with the glucocorticoid receptor (GR) i

87 pooled-protein strategy to test all 318,096 PPI combinations.

88 -helix-mediated protein-protein interaction (PPI) complex structures.

89 mixing ratios of 8:1, 8:1, 25:1 and 25:1 for PPI complexed with NP, MP42, MP37 and MP33, respectively

90 Protein-protein interactions (PPIs) control many important physiological processes wit

91 new reagents are still needed to help expand PPI coverage.

92 Using STRING and BioGrid PPI databases, we compared the coherence of 116 phenotyp

93 ns by reporting protein-protein interaction (PPI)-dependent, mutation-specific, and drug-driven chang

94 The strongest predictor of PPI discontinuation was number of days with acid exposur

95 e, but the effects of proton pump inhibitor (PPI) drugs are incompletely characterized.

96 Patient demographics, use of PPIs, duration of use and dose were recorded.

97 ical side chains of p53 and disrupt p53/MDM2 PPI effectively.

98 ests that Maillard conjugation could improve PPI emulsification properties.

99 After long-term PPI exposure, the fecal microbial profile was altered an

100 tabolic change are consequences of long-term PPI exposure.

101 ains, which provides insights into utilizing PPI for improved DR assessment.

102 nt prolonged wireless reflux monitoring (off PPIs for >=7 days) and a 3-week PPI cessation interventi

103 We identified new PPIs for receptors with well-characterized ligands and b

104 reater among the discontinued versus resumed PPI group (RESQ-eD, -43.7% vs -5.3%; P = .04).

105 ointestinal bleeding occurred in 1.3% of the PPI group and 1.8% of the H2RB group (risk ratio, 0.73 [

106 ysis; 2459 of 13 415 patients (18.3%) in the PPI group died at the hospital by day 90 and 2333 of 13

107 c reaction) was reported in 1 patient in the PPI group.

108 entire sample and 45.3% vs. 66.8% in the AC/PPI-group.

109 g 52 aiHp to 52 non-aiHp cases within the AC/PPI-group.

110 and in 192 of 373 patients (51.5%) in the AC/PPI-group.

111 Treatment of KI mice with PPIs had a clear clinical effect, showing a reduction in

112 BEST PRACTICE ADVICE 4: PPIs have no therapeutic value in functional heartburn,

113 stabilization of native PPIs, and non-native PPIs have received little consideration.

114 Proton pump inhibitors (PPIs) have been recognized as a primary treatment of eos

115 abilization of protein-protein interactions (PPIs) holds great potential for therapeutic agents, as i

116 Peptidomimetics have been applied to inhibit PPIs, however with variable success, as for certain inte

117 764 pairwise PPIs, a threefold increase over PPIs identified in one condition.

118 odel, we find no evidence for differences in PPI in a rat model of Fragile-X Syndrome (FXS) compared

119 of hyperdopaminergia, as well as normalizing PPI in DATKO mice.

120 l to examine the effects of long-term use of PPI in vivo.

121 s protein families and constructed 5,879,879 PPIs in all organisms using ChiPPI.

122 ducing effects as a therapeutic mechanism of PPIs in FD, with differential effects in HVs pointing to

123 s and benefits of prescribing and continuing PPIs in KTRs.

124 ng (FC), a reduction in prepulse inhibition (PPI) in the KO animal, along with a deterioration in mem

125 ling of a model protein-protein interaction (PPI) in vitro.

126 ifficulties associated with the targeting of PPIs, in particular when extended and flat protein inter

127 New PPIs include proteins expressed on multiple cell types a

128 thodology traditionally utilized to describe PPI, including that the underlying startle response has

129 However, the overall beany-related odor of PPIs increased when the germination time exceeded 1 day.

130 nduced systemic reactions are facilitated by PPI, ingestion of large amounts of unprocessed foods, an

131 ility for high-throughput screening (HTS) of PPI inhibitors.

132 eir function as protein-protein interaction (PPI) inhibitors.

133 ide scaffold derived from the FGF14:Na(v)1.6 PPI interface.

134 ers that differentiate between two different PPI interfaces of the adapter protein 14-3-3.

135 Medication with a PPI is the most common treatment, and after initial full

136 inhibition of the acoustic startle response (PPI) is a behavioral phenomenon studied extensively for

137 the PEX14-PEX5 protein-protein interaction (PPI) is an attractive way to affect multiple metabolic p

138 abilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery.

139 examination of protein-protein interactions (PPIs) is fundamental for the understanding of cellular m

140 complexity of protein-protein interactions (PPIs) is further compounded by the fact that an average

141 The use of PPIs led to a significant difference in absolute levels

142 inity of PPi to copper ions, the presence of PPi makes the etching process greatly suppressed, thereb

143 Cell-surface protein-protein interactions (PPIs) mediate cell-cell communication, recognition, and

144 Treatments include lifestyle modification, PPI medication, and laparoscopic fundoplication.

145 ssian distribution, and that the traditional PPI metric changes with different stimuli.

146 However, there is growing concerns about PPI misuse, overuse and abuse.

147 y structure mimetics as an emerging class of PPI modulators.

148 ased on time-resolved luminescence, enabling PPI monitoring even at low nanomolar protein concentrati

149 These methods are ideal for studying PPIs, most importantly as there is no need for labeling

150 In addition, it leverages the PPI network and Gene Ontology structure to further coord

151 as well as a classical version of the yeast PPI network in rigorous cross validation experiments.

152 GO enrichment analysis, KEGG pathways and PPI network indicated simultaneous utilization of leaf p

153 We found strong association between PPI network modulation and adaptation to specific habita

154 A PPI network provides crucial information on how biologic

155 tilized to automatically learn features from PPI network.

156 we performed a protein-protein interaction (PPI) network analysis of known intraflagellar transport,

157 enrichment and protein-protein interaction (PPI) network analysis.

158 uated through a protein-protein interaction (PPI) network combined with a co-expression network.

159 al structure in protein-protein interaction (PPI) network data that might mean that alternate methods

160 etworks such as protein-protein interaction (PPI) network, gene co-expression (CE) network and pathwa

161 to construct a protein-protein interaction (PPI) network, then the modules in the PPI networks were

162 es in the whole protein-protein interaction (PPI) network.

163 quence data and protein-protein interaction (PPI) network.

164 ncer biology based on published literatures, PPI-network and large-scale omics data.

165 reconstruction algorithms are applied to two PPI networks and assessed using both global and local de

166 this integration improves the quality of the PPI networks by reducing the number of false positive an

167 racteristic and precision-recall curves than PPI networks for both zebrafish and mouse.

168 based gene networks with mouse and zebrafish PPI networks retrieved from the STRING database and comp

169 Structural information of PPI networks such as their degree, position, and neighbo

170 Moreover, PPI networks suffer from network quality issues, which c

171 ut gene-anatomical entity relationships with PPI networks using anatomy ontology annotations.

172 ut gene-anatomical entity relationships with PPI networks via anatomy ontology improved the candidate

173 ction (PPI) network, then the modules in the PPI networks were analyzed with MCODE and the hub genes

174 with MCODE and the hub genes chose from the PPI networks were verified by Oncomine and TCGA database

175 d networks, which were semantically improved PPI networks, showed better performances by having highe

176 while ignoring the structural information of PPI networks.

177 Protein-protein interaction (PPI) networks are frequently used to predict disease gen

178 haracterize how protein-protein interaction (PPI) networks change, we quantified the relative PPI abu

179 cally, we built protein-protein interaction (PPI) networks with proteins encoded by AD- and psychosis

180 Most PPIs occur through small domains or motifs, which are ch

181 ect of 41 different sets of mutations in the PPI of the c-Raf-RBD:KRas complex.

182 Known PPIs of ciliary proteins were assembled from online data

183 entification and stabilization of non-native PPIs of N protein could be applied toward drug discovery

184 tial working memory and prepulse inhibition (PPI) of acoustic startle in Grin1 mutant mice.

185 we find altered protein-protein interaction (PPI) of mGluR5 with RGS4, norbin, Preso 1 and tamalin, w

186 s to redesign the protein-protein interface (PPI) of the c-Raf-RBD:KRas complex.

187 the predicted protein-protein interactions (PPIs) of all gene products, including those of stress-re

188 s of human esophageal cells to IL-13 and the PPIs omeprazole and esomeprazole were assessed by RT-PCR

189 These results demonstrate broad effects of PPIs on esophageal epithelium, including their ability t

190 KI and wild-type mice received PPIs or PBS intraperitoneally and were analyzed for surv

191 ng 79 SOT recipients (7.3%), and exposure to PPIs (OR 2.4, 95% CI 1.1-5.4) and third-generation cepha

192 terize Maillard conjugates from pea protein (PPI) or caseinate and dextran, and to evaluate the physi

193 ect and mechanism of proton pump inhibitors (PPIs) or first-line therapy remain unclear.

194 Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H2RBs) are often

195 erval [CI] 1.5-4.7), proton pump inhibitors (PPIs; OR 2.1, 95% CI 1.3-3.4), and exposure to third- (O

196 tified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral

197 of pH (8.0-1.5) and mixing ratio (1:1-30:1, PPI-pectin).

198 expression of QTL-linked genes, we nominated Ppid (peptidylprolyl isomerase D, a member of the tetrat

199 Protein-protein interactions (PPIs) play important roles in many biological processes.

200 l method we developed, called High-precision PPI Prediction (HiPPIP) model.

201 Our model can study PPI prediction based on both sequence information and gr

202 ploys a graph-based deep learning method for PPI prediction, which shows superiority over existing se

203 a graph has been proved to be informative in PPI prediction.

204 DI) prediction, protein-protein interaction (PPI) prediction; and 2 node classification tasks: medica

205 The modulation of PPIs presents opportunities to gain mechanistic insights

206 s the deficits in spatial working memory and PPI, presumably by restoration of synchronous GABA relea

207 These PPIs provide a resource for further biological investiga

208 nd to cluster according to habitat, based on PPIs rather than on sequence similarities.

209 heartburn, systematic workup revealed truly PPI-refractory and reflux-related heartburn in a minorit

210 f new therapies are needed for patients with PPI-refractory GERD symptoms.

211 referred to VA gastroenterology clinics for PPI-refractory heartburn, systematic workup revealed tru

212 Procedures were also performed in PPI-refractory patients with FD ("FD-stoppers") before a

213 nderlying esophageal epithelial responses to PPIs remain poorly understood.

214 tional design of small molecule enhancers of PPIs remains elusive.

215 ctions, such as protein-protein interaction (PPI), remains to be elucidated.

216 = 0.76 +/- 0.42) (pH = 7) for caseinate and PPI, respectively.

217 nts with typical reflux symptoms, inadequate PPI response, and absence of severe esophagitis, acid ex

218 urgitation, and/or chest pain and inadequate PPI response.

219 differences in the effects of LES on PPG and PPI responses compared with control interventions.

220 PPG and PPI responses were calculated as mean incremental area u

221 dial glucose (PPG) and postprandial insulin (PPI) responses, in order to comprehensively and objectiv

222 Functional analysis of the PPI-responsive, upregulated genes revealed enrichment in

223 y that could be used to clarify inconsistent PPI results in mice and humans.

224 Observed PPIs reveal a large and complex network of interactions

225 SDS-PAGE profile of PPI revealed major bands ranging from 50 to 7 kDa.

226 dependent of pH(phi1) increased to pH 5.5 as PPI-SBP mixing ratio increased to 20:1.

227 The effects of pH (7-2) and PPI-SBP mixing ratios (1:1-20:1) on coacervates formatio

228 Detailed analyses of the PpiD-SecY interaction by site-directed cross-linking rev

229 Mapping >6000 PPIs shows that this network is extensively rewired in c

230 y GERD, adding 1500 mg IW-3718 to label-dose PPIs significantly reduced heartburn symptoms compared w

231 atures of protein sequences are critical for PPI site prediction.

232 nd global sequence features, is proposed for PPI site prediction.

233 ional biological experiments for identifying PPI sites are costly and time-consuming.

234 lly use local contextual features to predict PPI sites.

235 nal approaches have been proposed to predict PPI sites.

236 al sequence features are combined to predict PPI sites.

237 cle size than conjugation and was lowest for PPI-stabilized emulsions.

238 proach to overcome the hurdles in systematic PPI stabilizer discovery.

239 oints for the development of specific 14-3-3 PPI stabilizers.

240 o receive label-dose proton pump inhibitors (PPIs) still have symptoms.

241 ageal epithelial cells robustly responded to PPI stimulation by inducing a set of 479 core genes comm

242 To offset the statistical limits of the PPI structure and sequence databases, amino acid-specifi

243 nsively for this purpose, but the results of PPI studies are often inconsistent.

244 hods have traditionally been widely used for PPI studies, label-free techniques have recently drawn s

245 evaluate these protein-protein interactions (PPIs), such as in vitro pull downs and coimmunoprecipita

246 products) in combination with preproinsulin (PPI) target antigen peptides.

247 d a 10 times increased odds of discontinuing PPI than participants with 4 days of AET > 4.0%.

248 s, the list of host endogenous and exogenous PPIs that can be disrupted, and tissue expression of the

249 atically reconstruct signaling pathways from PPIs that leverages cellular localization information ab

250 mic virus-host protein-protein interactions (PPIs) that are intrinsic to the spread of infections.

251 major motor disorders, and pH monitoring off PPI therapy (or pH-impedance monitoring on therapy in pa

252 FD ("FD-starters") and HVs before and after PPI therapy (pantoprazole 40 mg once daily for 4 weeks).

253 s in markers of bone turnover in women given PPI therapy compared with women given placebo, but level

254 ophageal ulcer), and pH impedance testing on PPI therapy demonstrates physiologic acid exposure witho

255 enal and systemic alterations in relation to PPI therapy in patients with FD and healthy volunteers (

256 eria when heartburn persists despite maximal PPI therapy in patients with history of proven GERD (ie,

257 Although a proportion do not require ongoing PPI therapy, a diagnostic approach to identify candidate

258 orrelated with eosinophils before and during PPI therapy, and increased eosinophils and permeability

259 8, a bile acid sequestrant, as an adjunct to PPI therapy.

260 igher in FD-starters vs HVs and reduced with PPI therapy.

261 Proton pump inhibitor (PPI) therapy fails to provide adequate symptom control i

262 maximal (double-dose) proton pump inhibitor (PPI) therapy taken appropriately before meals during a 3

263 nd there has been little success controlling PPIs through standard molecular library screening approa

264 Developing molecules that modulate PPIs through the interface of their protein surfaces has

265 We then develop a novel model that reveals PPI to be a combination of the previously appreciated sc

266 As a result of the strong affinity of PPi to copper ions, the presence of PPi makes the etchin

267 Furthermore, PPI treatment decreased the IL-13-induced proliferative

268 PPI treatment reversed approximately 20% of the IL-13 tr

269 One-month PPI treatment significantly decreased NOX5, mPGES1 and i

270 duced systemic reactions were independent of PPI treatment.

271 Twenty-six papers (34 PPG trials and 29 PPI trials) were included.

272 that the extinction-facilitating effects of Ppid upregulation were blocked by a GR antagonist.

273 Strategies to decrease PPI use and changes in the class of prophylactic antibio

274 The associations between PPI use and fractures remained similar in analyses limit

275 g off acid suppression can limit unnecessary PPI use and guide personalized management.

276 PPI use does not seem to cause significant changes in th

277 Clinicians should individualize PPI use in KTRs, evaluating the risks and benefits of pr

278 This study aimed to determine whether PPI use is associated with incidence of major fractures

279 Our objective was to identify the effects of PPI use on the microbial community of the esophagus.

280 PPI use remains the dominant treatment, but long-term th

281 PPI use was associated with higher incidence of major fr

282 15.0; P = 0.011), and proton pump inhibitor (PPI) use (OR, 3.50; 95% CI, 1.19 to 10.3; P = 0.023) wer

283 We also found that half of PPI users have persistent symptoms.

284 ategies were compared (preferential use with PPIs vs preferential use with H2RBs).

285 Extraction method for PPI was optimized by varying NaCl (0, 0.5, 1 M) and flou

286 The transcriptional response to PPIs was partially mediated through the aryl hydrocarbon

287 ake on the mean change difference in PPG and PPI were -0.02 mmol/L (95% CI: -0.09, 0.05) and -2.39 pm

288 eased eosinophils and permeability in HVs on PPIs were associated with changes in bile salts.

289 In total, 67 volatiles in PPIs were identified via HS-SPME-GC-MS/O.

290 subnetworks affected by blast fungus through PPIs were investigated.

291 xygenase and the free radical populations in PPIs were positively related to the overall beany-relate

292 Novel PPIs were predicted for each ciliary protein using a com

293 In this study, pulse protein isolates (PPIs) were extracted from 0, 1, 3, and 5 days germinated

294 Seventeen (19%) patients were taking a PPI when the systemic reaction occurred (vs 5% in contro

295 Proton pump inhibitors (PPIs), which are commonly used as inhibitors of gastric

296 Complexation of PPI with NP and MP42 greatly improved the protein solubi

297 -mixing ratio of 8:1, 8:1, 10:1 and 15:1 for PPI with UM88, M72, M42, and M9, respectively.

298 methodologies often prevent the detection of PPIs with low abundance proteins.

299 ctions through protein-protein interactions (PPIs) with client proteins.

300 FD ("FD-stoppers") before and 8 weeks after PPI withdrawal.

301 itoring predicted the ability to discontinue PPIs without symptom escalation.